Table 1 Characteristics of included studies
Author, year, country, Reference | Study design | Dose (mg) | Included number | LDL-C | HDL-C | TC | TG | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
E + A | A | Mean | Treatment difference (95% CI) | Mean | Treatment difference (95% CI) | Mean | Treatment difference (95% CI) | Mean | Treatment difference (95% CI) | |||
Matsue,Y., 2013,Japan,19 | randomized, open-labeled, parallel-group | E10 + A10/A20 | 115 | 128 | −16.7 | (−18.34,-15.06) | 0.47 | (−2.05,2.99) | −9.6 | (−11.07,-8.13) | −5.3 | (− 9.59,-1.01) |
Teramoto,T., 2012,Japan,20 | multicenter, randomized, open-label, parallel-group | E10 + A10/A20 | 47 | 46 | −10.6 | (−15.4,-5.8) | 4 | (−0.3,8.3) | − 7.6 | (− 11.4,− 3.8) | -3 | (−18.8,12.7) |
Ben-Yehuda,O., 2011,USA,21 | multicenter, randomized, double-blind, parallel-arm | (a)E10 + A10/A20 (b)E10 + A10/A20 | 404 111 | 408 107 | −13.6 − 14.5 | (− 16,-11.2) (− 19.1,-9.8) | 1.3 4.2 | (− 0.5,3.1) (0.7,7.6) | −7.8 − 8.4 | (−9.4,-6.2) (− 11.5,-5.3) | − 5.7 − 7.6 | (− 8.9,-2.4) (− 13.3,-2) |
Zieve,F., 2010,Russia,22 | multicenter, randomized, doubleblind, parallel-arm | E10 + A10/A20 | 515 | 515 | − 14 | (− 16,-12) | 2 | (0.3,4) | −8 | (− 9,-7) | −6 | (− 9,-3) |
Stein,E., 2004,Spain,23 | multicenter, randomized, double-blind, active-controlled | E10 + A10/A20 | 293 | 303 | −14.8 | (− 16.74,-12.86) | 0.8 | (− 0.86,2.46) | − 11.2 | (− 12.86,-9.54) | −5.4 | (− 10.11,-0.69) |
Padhy,B.M., 2013,India,24 | randomised, double-blind, parallel-group, comparator-controlled | E10 + A10/A10 | 15 | 15 | −19.9 | (−32.4,-7.4) | 6.3 | (−7.2,19.8) | −14.4 | (−27.7,-1) | −33 | (−54.1,-11.9) |
Blagden,M.D., 2007,UK,25 | randomised, double-blind, parallel-group, placebocontrolled | E10 + A10/A10 | 72 | 76 | −14.1 | (− 17.9,-10.2) | −0.3 | (−4.3,3.6) | −9.2 | (− 12.4,-6) | −8.3 | NR |
Bays,H.E., 2011,USA,26 | multicenter, randomized, double-blind, parallel-group | (a)E10 + A20/A40 (b)E10 + A20/A40 (c)E10 + A40/A80 (d)E10 + A40/A80 | 73 19 176 101 | 64 28 159 120 | −21.9 −13.8 − 15.4 − 18.3 | (− 28.1,-15.6) (− 24.6,-3) (− 19.4,-11.3) (− 23.2,-13.3) | 3 − 0.1 − 0.2 1.5 | (−1.9,7.9) (− 8.7,8.5) (− 2.3,1.9) (−1.1,4.1) | − 13.2 − 9.4 − 9.6 − 10.7 | (− 17.5,-9) (− 16.7,-2.1) (− 12.3,-7) (− 13.9,-7.4) | −7.6 − 11.8 − 6.7 − 7.9 | (−19,3) (− 25.4,1.3) (− 12.5,-1.2) (− 14.5,-1.7) |
Conard,S.E., 2008,USA,27 | multicenter, randomized, double-blind, parallel-group | E10 + A20/A40 | 92 | 92 | −20 | (−25,-15) | 2 | (−2,7) | −12 | (− 16,− 9) | -9 | (− 18,0) |
Conard,S.E., 2010,USA,28 | multicentre, randomized, double-blind, parallel-group | (a)E10 + A40/A80 (b)E10 + A40/A80 (c)E10 + A40/A80 | 61 67 149 | 66 68 145 | −14.3 − 16 − 17.4 | (− 20.9,-7.8) (− 22.3,-9.6) (− 21.7,-13.1) | 2 1.9 − 0.8 | (−1.4,5.4) (−1.4,5.2) (− 3,1.4 | −8.9 − 10.1 − 10.4 | (−13.2,-4.6) (− 14.2,-5.9) (− 13.2,-7.6) | −6.4 − 7.2 − 7.7 | (− 15.1,2.3) (− 15.9,1.6) (− 13.6,-1.8) |
Leiter,L.A., 2008,Canada,29 | multicenter, randomized, double-blind, parallel-group | E10 + A40/A80 | 277 | 279 | −16 | (−19,-13) | 0 | (−1,2) | −10 | (− 12,-8) | − 7 | (− 11,-3) |